Medical Cannabis

Informative speech
Background
The botanical origin of
Cannabis is suspected to
be from Western and
Central Asia
Contos
o
Pharmaceuticals
page 2
Timeline
Our two-year action plan

Trials Marketing Launch

Month, 20YY Month, 20YY Month, 20YY

AUG SEP OCT NOV DEC JAN FEB MAR APR MAY JUN JUL AUG SEP OCT NOV DEC JAN FEB MAR APR MAY

20YY 20YY

Legislation Investment Procurement

Month, 20YY Month, 20YY Month, 20YY

Contos
o
Pharmaceuticals
page 3
 Chemical
THC CBD Naboline components
Tetrahidrocannabinol component of
Epidiolex
psychological effects treat nauseas and
people with seizures vomiting

Contos
o
Pharmaceuticals
page 4
• The Cannabis might • The people can take it

Contos
o
Pharmaceuticals
page 5
• Lorem ipsum dolor sit amet, consectetur
adipiscing elit.
• Ut fermentum a magna ut eleifend. Integer
Background
convallis suscipit ante eu varius.
The botanical origin of cannabis is
• Morbi a purus dolor. Suspendisse sit amet suspected to be from Western and
ipsum finibus justo viverra blandit.
Central Asia
• Ut congue quis tortor eget sodales.
Contos
o
Pharmaceuticals
page 6
Ilness

Cancer Epilepsy Muscle spasms

COO COB CFO

Lorem ipsum dolor sit amet,
consectetur adipiscing elit. Etiam
aliquet eu mi quis lacinia. Ut
fermentum a magna ut eleifend.
Integer convallis suscipit ante eu
varius.
Morbi a purus dolor. Suspendisse sit
amet ipsum finibus justo viverra
blandit. Ut congue quis tortor eget
sodales. Nulla a erat eget nunc
hendrerit ultrices eu nec nulla.
Donec viverra leo aliquet, auctor quam
id, convallis orci. Sed in molestie est.
Cras ornare turpis at ligula posuere, sit
amet accumsan neque lobortis.

Contos
o
Pharmaceuticals
page 7
Team Alternate

Mirjam Victoria Alexander

Nilsson Lindqvist Martensson
COO COB CFO

Angelica Mira Flora

Astrom Karlsson Berggren
Head of Operations Head of Technical Creative Director

Contos
o
Pharmaceuticals
page 8
The Problem

Declining Market Financial Trust Cost Margins

Lorem ipsum dolor sit Etiam aliquet eu mi Integer convallis Suspendisse sit amet Ut congue quis tortor
amet, consectetur quis lacinia. Ut suscipit ante eu ipsum varius finibus varius eget sodales.
adipiscing elit. fermentum a magna varius. Morbi a purus justo viverra blandit.
ut eleifend. dolor.

Contos
o
Pharmaceuticals
page 9
 Unique First to Market
Lorem ipsum dolor sit Etiam aliquet eu mi.
amet, consectetur Ut fermentum a
adipiscing elit. magna ut eleifend.

Product
Lorem ipsum dolor sit amet,
consectetur adipiscing elit.
Tested Authentic Etiam aliquet eu mi quis.
Integer convallis Suspendisse sit amet
suscipit eu varius. ipsum varius finibus
Morbi a purus dolor. justo viverra blandit.
Contos
o
Pharmaceuticals
page 10
Emphasize your

main benefit
Other benefits include
• Lorem ipsum dolor sit amet,
consectetur adipiscing elit.
• Nunc tempus, risus sodales hendrerit,
arcu dolor commodo libero.
Contos
o
Pharmaceuticals
page 11
Section Divider
Lorem ipsum dolor sit amet,
consectetur adipiscing elit Contos
o
Pharmaceuticals
page 12
Business Model
Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Research Finance Invest

Lorem ipsum dolor sit Etiam aliquet eu mi Integer convallis
amet, consectetur quis lacinia. Ut suscipit ante eu
adipiscing elit. fermentum a magna varius. Morbi a purus
ut eleifend. dolor.

Contos
o
Pharmaceuticals
page 13
Market Opportunity Option 1
Lorem ipsum dolor sit amet, consectetur adipiscing elit.

$1B
• Lorem ipsum dolor sit amet,
$2B
• Ut congue quis tortor eget
consectetur adipiscing elit. sodales. Nulla a erat eget
nunc hendrerit ultrices eu nec
• Etiam aliquet eu mi quis
nulla.
lacinia. Ut fermentum a
magna ut eleifend. Integer • Donec viverra leo aliquet,
convallis suscipit ante eu auctor quam id, convallis orci.
varius.
• Morbi a purus dolor.
Suspendisse sit amet ipsum
finibus justo viverra blandit.
Contos
o
Pharmaceuticals
page 14
Market Opportunity Option 2
Integer convallis suscipit ante eu varius. Morbi a purus dolor.

$3B
Opportunity to Build
$2B
Freedom to Invent
$1B
Few Competitors

Lorem ipsum dolor sit Etiam aliquet eu mi quis Integer convallis suscipit
amet, consectetur lacinia. Ut fermentum a ante eu varius. Morbi a
adipiscing elit. magna ut eleifend. purus dolor.

Contos
o
Pharmaceuticals
page 15
Competition Option 1

Contoso Pharmaceuticals Competitor

• Nulla a erat eget nunc hendrerit ultrices eu nec
nulla. Donec viverra leo aliquet, auctor quam id,
convallis orci.
• Sed in molestie est. Cras ornare turpis at ligula
posuere, sit amet accumsan neque lobortis.
• Maecenas mattis risus ligula, sed ullamcorper nunc
efficitur sed.
• Praesent venenatis quam tortor, id viverra nunc
rutrum a.
• Maecenas malesuada ultricies sapien sit amet
pharetra.
• Nunc tempus, risus sodales hendrerit, arcu dolor
commodo libero, a sollicitudin quam nulla quis
lectus. In at porta mauris.

Contos
o
Pharmaceuticals
page 16
Competition Option 2
Convenience

Contoso
Pharmaceuticals

Expensive Affordable

Inconvenient Contos
o
Pharmaceuticals
page 17
Growth Strategy
How will we scale in the future
Phase 1
Month, Year
• Lorem ipsum dolor sit
amet, consectetur
adipiscing elit.
• Etiam aliquet eu mi quis
lacinia. Ut fermentum a
magna ut eleifend.
Integer convallis suscipit
ante eu varius.
Phase 2 Phase 3
Month, Year Month, Year
• Morbi a purus dolor. • Donec viverra leo
Suspendisse sit amet aliquet, auctor quam id,
ipsum finibus justo convallis orci.
viverra blandit.
• Lorem ipsum dolor sit
• Ut congue quis tortor amet, consectetur
eget sodales. Nulla a erat adipiscing elit.
eget nunc hendrerit
ultrices eu nec nulla.
Contos
o
Pharmaceuticals
page 18
Traction
Forecasting for success

Vendors Users Gross Company

Revenue Revenue

20YY 0 0 $0 $0

20YY 10 100 $6,750 $1,013

20YY 50 500 $33,750 $5,063

20YY 200 2000 $135,000 $20,250

20YY 400 4000 $270,000 $40,500

Contos
o
Pharmaceuticals
page 19
Financials
Year 1 Year 2 Year 3
Detailers 5,000 40,000 160,000
Users 50,000 400,000 1 600,000
Sales 500,000 4 000,000 16 000,000
Average Price per Sale 75 80 90
Revenue @ 15% 5 625,000 48 000,000 216 000,000
• Cost of Revenue 0 0 0
Gross Profit 5 625,000 48 000,000 216 000,000
Expenses
• Sales & Marketing 5 062,500 38 400,000 151 200,000 70%
• Customer Service 1 687,500 9 600,000 21 600,000 10%

• Product
Development 562,500 2 400,000 10 800,000 5%
• Research 281,250 2 400,000 4 320,000 2%
Total Expenses 7 593,750 52 800,000 187 920,000
Contos
EBIT -1 968,750 -4 800,000 28 080,000 13% o
Pharmaceuticals
page 20
Funding

Fund Category Fund Category

Etiam aliquet eu mi quis lacinia.
Lorem ipsum dolor sit amet,
Ut fermentum a magna ut.
consectetur adipiscing elit.

Fund Category Fund Category

. Integer convallis suscipit ante eu Suspendisse sit amet ipsum finibus
varius. Morbi a purus dolor. justo viverra blandit. Ut congue quis
tortor eget sodales. Contos
o
Pharmaceuticals
page 21
• Lorem ipsum dolor sit amet, consectetur
adipiscing elit. Etiam aliquet eu mi quis
lacinia. Summary
• Ut fermentum a magna ut eleifend. Integer
convallis suscipit ante eu varius. Morbi a Summary tagline or
purus dolor. Suspendisse sit amet ipsum sub-headline
finibus justo viverra blandit.
• Ut congue quis tortor eget sodales. Nulla a
erat eget nunc hendrerit ultrices eu. Contos
o
Pharmaceuticals
page 22
Thank You
April Hansson

+1 23 987 6554
april@contoso.com
Contos
www.contoso.com o
Pharmaceuticals
page 23
Customize this Template

Template Editing
Instructions and Feedback

Contos
o
Pharmaceuticals
page 24